These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30421554)

  • 1. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
    Chouhan H; Sammour T; L Thomas M; W Moore J
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
    Chouhan H; Sammour T; Thomas ML; Moore JW
    J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.
    Taieb J; Sinicrope FA; Pederson L; Lonardi S; Alberts SR; George TJ; Yothers G; Van Cutsem E; Saltz L; Ogino S; Kerr R; Yoshino T; Goldberg RM; André T; Laurent-Puig P; Shi Q
    Ann Oncol; 2023 Nov; 34(11):1025-1034. PubMed ID: 37619846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
    Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
    J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.
    Bruzzi M; Auclin E; Lo Dico R; Voron T; Karoui M; Espin E; Cianchi F; Weitz J; Buggenhout A; Malafosse R; Denimal F; Le Malicot K; Vernerey D; Douard R; Emile JF; Lepage C; Laurent-Puig P; Taieb J
    Ann Surg Oncol; 2019 Oct; 26(11):3561-3567. PubMed ID: 31209667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
    Ogino S; Shima K; Meyerhardt JA; McCleary NJ; Ng K; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Spiegelman D; Goldberg RM; Bertagnolli MM; Fuchs CS
    Clin Cancer Res; 2012 Feb; 18(3):890-900. PubMed ID: 22147942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
    Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
    J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
    Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
    Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
    Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status.
    Patil DT; Shadrach BL; Rybicki LA; Leach BH; Pai RK
    Mod Pathol; 2012 Oct; 25(10):1423-31. PubMed ID: 22684223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in sporadic colon cancer with high-level microsatellite instability.
    Oh BY; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
    Surgery; 2016 May; 159(5):1372-81. PubMed ID: 26775578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.
    Fariña-Sarasqueta A; van Lijnschoten G; Moerland E; Creemers GJ; Lemmens VEPP; Rutten HJT; van den Brule AJC
    Ann Oncol; 2010 Dec; 21(12):2396-2402. PubMed ID: 20501503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
    Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
    JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
    Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.